{"id":47,"date":"2020-01-22T10:15:21","date_gmt":"2020-01-22T10:15:21","guid":{"rendered":"https:\/\/www.almacgroup.com\/diagnostics\/?page_id=47"},"modified":"2025-02-26T12:58:02","modified_gmt":"2025-02-26T12:58:02","slug":"trusighttumor170","status":"publish","type":"page","link":"https:\/\/www.almacgroup.com\/diagnostics\/trusighttumor170\/","title":{"rendered":"DNA Panel Solution"},"content":{"rendered":"\n<p><strong>Almac Clinical Trial Assay<\/strong><\/p>\n\n\n\n<p>Almac Diagnostic Services has invested in the validation of this CLIA compliant assay and the full validation report is available on request.<\/p>\n\n\n\n<p><a href=\"\/diagnostics\/wp-content\/uploads\/sites\/3\/2020\/03\/21358-ALMAC-Diagnostics-TST170-Assay-Sheet-D1.pdf\" target=\"_blank\" rel=\"noreferrer noopener\" aria-label=\" (opens in a new tab)\"><strong>Read the Validation Performance Specification<\/strong><\/a><\/p>\n\n\n\n<p>This Almac Diagnostic Services clinical trial assay will provide Pharmaceutical and Biotech companies with a new option in the marketplace to support their clinical trials and CDx development. The assay, based on the Illumina TruSight\u2122 Tumor 170 chemistry and NextSeq platform, allows multiple biomarkers to be evaluated from one sample, thereby reducing the quantity of precious tissue sample necessary and offering a highly cost effective solution that will ultimately be kit-able further downstream.<\/p>\n\n\n\n<p>Almac Diagnostic Services offer clients powerful reporting for the assay through our own bioinformatics pipeline and software solution providing enhanced variant call reproducibility, accuracy and QC.<\/p>\n\n\n\n<p><a href=\"\/diagnostics\/contact-us\/\">Contact us today<\/a> to discuss your requirements for future clinical trial enrichment.<\/p>\n\n\n\n<p><strong>Almac RUO Assay <\/strong><\/p>\n\n\n\n<p>Almac Diagnostic Services also offer Illumina TruSight\u2122&nbsp;Tumor 170 panel as a research use only (RUO) assay. Should clients need further RUO interpretation of detected variants, Almac can offer \u2018IBM &#8211; Watson for Genomics\u2019 reporting for processed samples.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Almac Clinical Trial Assay Almac Diagnostic Services has invested in the validation of this CLIA compliant assay and the full validation report is available on request. Read the Validation Performance Specification This Almac Diagnostic Services clinical trial assay will provide Pharmaceutical and Biotech companies with a new option in the marketplace to support their clinical [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"template-dna.php","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-47","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.3.1 (Yoast SEO v26.3) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>DNA Panel Solution - Diagnostic Services<\/title>\n<meta name=\"description\" content=\"Discover Almac&#039;s validated Illumina TruSight\u2122 Tumor 170 cancer mutation panel. The assay is CLIA compliant for prospective clinical trial use, including Europe and the US\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.almacgroup.com\/diagnostics\/trusighttumor170\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"DNA Panel Solution\" \/>\n<meta property=\"og:description\" content=\"Discover Almac&#039;s validated Illumina TruSight\u2122 Tumor 170 cancer mutation panel. The assay is CLIA compliant for prospective clinical trial use, including Europe and the US\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.almacgroup.com\/diagnostics\/trusighttumor170\/\" \/>\n<meta property=\"og:site_name\" content=\"Diagnostic Services\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-26T12:58:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.almacgroup.com\/diagnostics\/wp-content\/uploads\/sites\/3\/2020\/11\/Almac_Logo-e1698941154737.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"100\" \/>\n\t<meta property=\"og:image:height\" content=\"52\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.almacgroup.com\/diagnostics\/trusighttumor170\/\",\"url\":\"https:\/\/www.almacgroup.com\/diagnostics\/trusighttumor170\/\",\"name\":\"DNA Panel Solution - Diagnostic Services\",\"isPartOf\":{\"@id\":\"https:\/\/www.almacgroup.com\/diagnostics\/#website\"},\"datePublished\":\"2020-01-22T10:15:21+00:00\",\"dateModified\":\"2025-02-26T12:58:02+00:00\",\"description\":\"Discover Almac's validated Illumina TruSight\u2122 Tumor 170 cancer mutation panel. The assay is CLIA compliant for prospective clinical trial use, including Europe and the US\",\"breadcrumb\":{\"@id\":\"https:\/\/www.almacgroup.com\/diagnostics\/trusighttumor170\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.almacgroup.com\/diagnostics\/trusighttumor170\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.almacgroup.com\/diagnostics\/trusighttumor170\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.almacgroup.com\/diagnostics\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"DNA Panel Solution\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.almacgroup.com\/diagnostics\/#website\",\"url\":\"https:\/\/www.almacgroup.com\/diagnostics\/\",\"name\":\"Diagnostic Services\",\"description\":\"Just another Almac Core Sites site\",\"publisher\":{\"@id\":\"https:\/\/www.almacgroup.com\/diagnostics\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.almacgroup.com\/diagnostics\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.almacgroup.com\/diagnostics\/#organization\",\"name\":\"Almac Group Ltd\",\"url\":\"https:\/\/www.almacgroup.com\/diagnostics\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/www.almacgroup.com\/diagnostics\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.almacgroup.com\/diagnostics\/wp-content\/uploads\/sites\/3\/2020\/04\/almac-logo-with-strapline.jpg\",\"contentUrl\":\"https:\/\/www.almacgroup.com\/diagnostics\/wp-content\/uploads\/sites\/3\/2020\/04\/almac-logo-with-strapline.jpg\",\"width\":643,\"height\":296,\"caption\":\"Almac Group Ltd\"},\"image\":{\"@id\":\"https:\/\/www.almacgroup.com\/diagnostics\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"DNA Panel Solution - Diagnostic Services","description":"Discover Almac's validated Illumina TruSight\u2122 Tumor 170 cancer mutation panel. The assay is CLIA compliant for prospective clinical trial use, including Europe and the US","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.almacgroup.com\/diagnostics\/trusighttumor170\/","og_locale":"en_GB","og_type":"article","og_title":"DNA Panel Solution","og_description":"Discover Almac's validated Illumina TruSight\u2122 Tumor 170 cancer mutation panel. The assay is CLIA compliant for prospective clinical trial use, including Europe and the US","og_url":"https:\/\/www.almacgroup.com\/diagnostics\/trusighttumor170\/","og_site_name":"Diagnostic Services","article_modified_time":"2025-02-26T12:58:02+00:00","og_image":[{"width":100,"height":52,"url":"https:\/\/www.almacgroup.com\/diagnostics\/wp-content\/uploads\/sites\/3\/2020\/11\/Almac_Logo-e1698941154737.jpeg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Estimated reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.almacgroup.com\/diagnostics\/trusighttumor170\/","url":"https:\/\/www.almacgroup.com\/diagnostics\/trusighttumor170\/","name":"DNA Panel Solution - Diagnostic Services","isPartOf":{"@id":"https:\/\/www.almacgroup.com\/diagnostics\/#website"},"datePublished":"2020-01-22T10:15:21+00:00","dateModified":"2025-02-26T12:58:02+00:00","description":"Discover Almac's validated Illumina TruSight\u2122 Tumor 170 cancer mutation panel. The assay is CLIA compliant for prospective clinical trial use, including Europe and the US","breadcrumb":{"@id":"https:\/\/www.almacgroup.com\/diagnostics\/trusighttumor170\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.almacgroup.com\/diagnostics\/trusighttumor170\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.almacgroup.com\/diagnostics\/trusighttumor170\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.almacgroup.com\/diagnostics\/"},{"@type":"ListItem","position":2,"name":"DNA Panel Solution"}]},{"@type":"WebSite","@id":"https:\/\/www.almacgroup.com\/diagnostics\/#website","url":"https:\/\/www.almacgroup.com\/diagnostics\/","name":"Diagnostic Services","description":"Just another Almac Core Sites site","publisher":{"@id":"https:\/\/www.almacgroup.com\/diagnostics\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.almacgroup.com\/diagnostics\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"},{"@type":"Organization","@id":"https:\/\/www.almacgroup.com\/diagnostics\/#organization","name":"Almac Group Ltd","url":"https:\/\/www.almacgroup.com\/diagnostics\/","logo":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/www.almacgroup.com\/diagnostics\/#\/schema\/logo\/image\/","url":"https:\/\/www.almacgroup.com\/diagnostics\/wp-content\/uploads\/sites\/3\/2020\/04\/almac-logo-with-strapline.jpg","contentUrl":"https:\/\/www.almacgroup.com\/diagnostics\/wp-content\/uploads\/sites\/3\/2020\/04\/almac-logo-with-strapline.jpg","width":643,"height":296,"caption":"Almac Group Ltd"},"image":{"@id":"https:\/\/www.almacgroup.com\/diagnostics\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.almacgroup.com\/diagnostics\/wp-json\/wp\/v2\/pages\/47","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.almacgroup.com\/diagnostics\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.almacgroup.com\/diagnostics\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.almacgroup.com\/diagnostics\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.almacgroup.com\/diagnostics\/wp-json\/wp\/v2\/comments?post=47"}],"version-history":[{"count":14,"href":"https:\/\/www.almacgroup.com\/diagnostics\/wp-json\/wp\/v2\/pages\/47\/revisions"}],"predecessor-version":[{"id":4160,"href":"https:\/\/www.almacgroup.com\/diagnostics\/wp-json\/wp\/v2\/pages\/47\/revisions\/4160"}],"wp:attachment":[{"href":"https:\/\/www.almacgroup.com\/diagnostics\/wp-json\/wp\/v2\/media?parent=47"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}